midazolam has been researched along with pci 32765 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cordoba, R; de Jong, J; Dlugosz-Danecka, M; Hellemans, P; Jiao, J; Jurczak, W; Mitselos, A; Ouellet, D; Panizo, C; Sukbuntherng, J; Wrobel, T | 1 |
| Fallon, JK; Jackson, KD; Lee, J; Smith, PC | 1 |
1 trial(s) available for midazolam and pci 32765
| Article | Year |
|---|---|
Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Area Under Curve; Bupropion; Contraceptives, Oral; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Drug Interactions; Ethinyl Estradiol; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Levonorgestrel; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Mantle-Cell; Metabolic Clearance Rate; Midazolam; Middle Aged; Piperidines; Waldenstrom Macroglobulinemia | 2020 |
1 other study(ies) available for midazolam and pci 32765
| Article | Year |
|---|---|
Formation of CYP3A-specific metabolites of ibrutinib in vitro is correlated with hepatic CYP3A activity and 4β-hydroxycholesterol/cholesterol ratio.
Topics: Biomarkers; Cholesterol; Cytochrome P-450 CYP3A; Humans; Infant; Liver; Midazolam | 2023 |